Journal of Peking University (Health Sciences) ›› 2024, Vol. 56 ›› Issue (4): 562-564. doi: 10.19723/j.issn.1671-167X.2024.04.002
Previous Articles Next Articles
树栋 张*(
),睿扬 谢
CLC Number:
- R737.1
| 1 |
Marshall FF , Dietrick DD , Baumgartner WA , et al. Surgical management of renal cell carcinoma with intracaval neoplastic extension above the hepatic veins[J]. J Urol, 1988, 139 (6): 1166- 1172.
doi: 10.1016/S0022-5347(17)42848-5 |
| 2 |
Reese AC , Whitson JM , Meng MV . Natural history of untreated renal cell carcinoma with venous tumor thrombus[J]. Urol Oncol, 2013, 31 (7): 1305- 1309.
doi: 10.1016/j.urolonc.2011.12.006 |
| 3 |
Tilki D , Nguyen HG , Dall-Era MA , et al. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus[J]. Eur Urol, 2014, 66 (3): 577- 583.
doi: 10.1016/j.eururo.2013.06.048 |
| 4 | 黄庆波, 彭程, 顾良友, 等. 肾肿瘤伴静脉瘤栓"301分级系统"及手术策略(附100例病例分析)[J]. 微创泌尿外科杂志, 2017, 6 (6): 328- 332. |
| 5 |
Aslam-Sohaib SA , Teh J , Nargund VH , et al. Assessment of tumor invasion of the vena caval wall in renal cell carcinoma cases by magnetic resonance imaging[J]. J Urol, 2002, 167 (3): 1271- 1275.
doi: 10.1016/S0022-5347(05)65280-9 |
| 6 | Zargar-Shoshtari K , Sharma P , Espiritu P , et al. Caval tumor thrombus volume influences outcomes in renal cell carcinoma with venous extension[J]. Urol Oncol, 2015, 33 (3): 112. |
| 7 | Tabbara MM, Gonzalez J, Ciancio G. Renal cell carcinoma with supradiaphragmatic tumor thrombus: Avoiding sternotomy and cardiopulmonary bypass[J]. Med Res Arch, 2022(2022-07-31)[20230-1-15]. https://pubmed.ncbi.nlm.nih.gov/36714035. |
| 8 |
Thiel DD , Lohse CM , Arnold ML , et al. Does left side renal cell carcinoma (RCC) with renal vein/vena cava thrombus predict worse prognosis than equivalent right side RCC tumor thrombus?[J]. Int Urol Nephrol, 2012, 44 (4): 1005- 1012.
doi: 10.1007/s11255-012-0168-2 |
| 9 |
Zhang Y , Bi H , Fu Y , et al. Cephalic inferior vena cava non-clamping technique versus standard procedure for robot-assisted laparoscopic level Ⅱ-Ⅲ thrombectomy: A prospective cohort study[J]. Int J Surg, 2023, 109 (6): 1594- 1602.
doi: 10.1097/JS9.0000000000000209 |
| 10 |
Cost NG , Delacroix SE , Jr. , Sleeper JP , et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus[J]. Eur Urol, 2011, 59 (6): 912- 918.
doi: 10.1016/j.eururo.2011.02.032 |
| 11 |
Bigot P , Fardoun T , Bernhard JC , et al. Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: Is it useful?[J]. World J Urol, 2014, 32 (1): 109- 114.
doi: 10.1007/s00345-013-1088-1 |
| 12 |
Zhang Y , Li Y , Deng J , et al. Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma[J]. PLoS One, 2015, 10 (2): e0115896.
doi: 10.1371/journal.pone.0115896 |
| 13 |
Field CA , Cotta BH , Jimenez J , et al. Neoadjuvant sunitinib decreases inferior vena caval thrombus size and is associated with improved oncologic outcomes: A multicenter comparative analysis[J]. Clin Genitourin Cancer, 2019, 17 (3): e505- e512.
doi: 10.1016/j.clgc.2019.01.013 |
| 14 |
Stewart GD , Welsh SJ , Ursprung S , et al. A Phase Ⅱ study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)[J]. Br J Cancer, 2022, 127 (6): 1051- 1060.
doi: 10.1038/s41416-022-01883-7 |
| 15 |
Zhang Z , Xiong L , Wu Z , et al. Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma[J]. Transl Androl Urol, 2021, 10 (5): 2091- 2102.
doi: 10.21037/tau-21-406 |
| 16 |
Labbate C , Hatogai K , Werntz R , et al. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy[J]. J Immunother Cancer, 2019, 7 (1): 66.
doi: 10.1186/s40425-019-0546-8 |
| 17 |
Hara T , Terakawa T , Hyodo T , et al. Pathological complete response of renal cell carcinoma with vena cava tumor thrombus to neoadjuvant TKI/IO combination therapy[J]. Urol Case Rep, 2021, 39, 101800.
doi: 10.1016/j.eucr.2021.101800 |
| 18 |
Powles T , Tomczak P , Park SH , et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2022, 23 (9): 1133- 1144.
doi: 10.1016/S1470-2045(22)00487-9 |
| 19 |
Choueiri TK , Tomczak P , Park SH , et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma[J]. N Engl J Med, 2021, 385 (8): 683- 694.
doi: 10.1056/NEJMoa2106391 |
| 20 |
Wu Z , Chen H , Chen Q , et al. Prognostic significance of grade discrepancy between primary tumor and venous thrombus in nonmetastatic clear-cell renal cell carcinoma: Analysis of the REMEMBER registry and implications for adjuvant therapy[J]. Eur Urol Oncol, 2024, 7 (1): 112- 121.
doi: 10.1016/j.euo.2023.06.006 |
| [1] | Haoming YIN, Zijie WANG, Fan SHU, Zhanyi ZHANG, Hui LIANG, Shudong ZHANG. Expression and significance of the FABP6 long transcript in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 393-398. |
| [2] | Shenmo LI, Dandan SU, Jiyu LIN, Haodong SONG, Lulin MA, Xiaofei HOU, Guoliang WANG, Hongxian ZHANG, Jianfei YE, Shudong ZHANG. Prognostic analysis of laparoscopic simultaneous radical cystectomy and nephroureterectomy [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 961-966. |
| [3] | Boda GUO, Min LU, Guoliang WANG, Hongxian ZHANG, Lei LIU, Xiaofei HOU, Lei ZHAO, Xiaojun TIAN, Shudong ZHANG. Clinicopathological and prognostic differences between clear cell and non-clear cell renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 644-649. |
| [4] | Zhanyi ZHANG, Min LU, Yuehao SUN, Jinghan DONG, Xiaofei HOU, Chunlei XIAO, Guoliang WANG, Xiaojun TIAN, Lulin MA, Hongxian ZHANG, Shudong ZHANG. Clinicopathological features and survival analysis of TFE3-rearranged renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 650-661. |
| [5] | Qi MIAO, Baoan HONG, Xuezhou ZHANG, Zhipeng SUN, Wei WANG, Yuxuan WANG, Yuxuan BO, Jiahui ZHAO, Ning ZHANG. Risk assessment of perioperative adverse events and management of antiplatelet therapy in patients with bladder cancer and coronary atherosclerotic heart disease undergoing transurethral resection of bladder cancer [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 698-703. |
| [6] | Zezhen ZHOU, Liyuan GE, Fan ZHANG, Shaohui DENG, Ye YAN, Hongxian ZHANG, Guoliang WANG, Lei LIU, Yi HUANG, Shudong ZHANG. A retrospective matching study of partial nephrectomy and radical nephrectomy for pathological T3a stage renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 704-710. |
| [7] | Shuai LIU, Zhuo LIU, Yunhe GUAN, Guoliang WANG, Xiaojun TIAN, Hongxian ZHANG, Lei LIU, Lulin MA, Shudong ZHANG. Robot-assisted laparoscopic inferior vena cava segmental resection for renal tumor with tumor thrombus invading the vascular wall [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 796-802. |
| [8] | Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679. |
| [9] | Binshuai WANG,Min QIU,Qianjin ZHANG,Maofeng TIAN,Lei LIU,Guoliang WANG,Min LU,Xiaojun TIAN,Shudong ZHANG. Experience in diagnosis and treatment of 6 cases of renal Ewing's sarcoma with venous thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 636-639. |
| [10] | Jie YANG,Jieli FENG,Shudong ZHANG,Lulin MA,Qing ZHENG. Clinical effects of transesophageal echocardiography in different surgical methods for nephrectomy combined with Mayo Ⅲ-Ⅳ vena tumor thrombectomy [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 631-635. |
| [11] | Kewei CHEN,Zhuo LIU,Shaohui DENG,Fan ZHANG,Jianfei YE,Guoliang WANG,Shudong ZHANG. Clinical diagnosis and treatment of renal angiomyolipoma with inferior vena cava tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 617-623. |
| [12] | Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588. |
| [13] | Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666. |
| [14] | Fan SHU,Yichang HAO,Zhanyi ZHANG,Shaohui DENG,Hongxian ZHANG,Lei LIU,Guoliang WANG,Xiaojun TIAN,Lei ZHAO,Lulin MA,Shudong ZHANG. Functional and oncologic outcomes of partial nephrectomy for cystic renal cell carcinoma: A single-center retrospective study [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 667-672. |
| [15] | Kewei CHEN,Shaohui DENG,Zhuo LIU,Hongxian ZHANG,Lulin MA,Shudong ZHANG. Discussion on the surgical timing of rupture and hemorrhage of renal angiomyolipoma [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 326-331. |
|
||